SG10201405392RA - Method of treatment of neurodegenerative or neuro-muscular degenerative diseases andtherapeutic agent to treat the same - Google Patents
Method of treatment of neurodegenerative or neuro-muscular degenerative diseases andtherapeutic agent to treat the sameInfo
- Publication number
- SG10201405392RA SG10201405392RA SG10201405392RA SG10201405392RA SG10201405392RA SG 10201405392R A SG10201405392R A SG 10201405392RA SG 10201405392R A SG10201405392R A SG 10201405392RA SG 10201405392R A SG10201405392R A SG 10201405392RA SG 10201405392R A SG10201405392R A SG 10201405392RA
- Authority
- SG
- Singapore
- Prior art keywords
- andtherapeutic
- neuro
- neurodegenerative
- treat
- agent
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/315—Zinc compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/30—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Neurology (AREA)
- Dermatology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Inorganic Chemistry (AREA)
- Otolaryngology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Biochemistry (AREA)
- Psychiatry (AREA)
- Toxicology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN2149CH2009 | 2009-09-04 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10201405392RA true SG10201405392RA (en) | 2014-10-30 |
Family
ID=43649728
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201405392RA SG10201405392RA (en) | 2009-09-04 | 2010-09-02 | Method of treatment of neurodegenerative or neuro-muscular degenerative diseases andtherapeutic agent to treat the same |
| SG2012014635A SG178942A1 (en) | 2009-09-04 | 2010-09-02 | Method of treatment of neurodegenerative or neuro-muscular degenerative diseases and therapeutic agent to treat the same |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG2012014635A SG178942A1 (en) | 2009-09-04 | 2010-09-02 | Method of treatment of neurodegenerative or neuro-muscular degenerative diseases and therapeutic agent to treat the same |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US8962039B2 (en) |
| EP (1) | EP2473037B1 (en) |
| JP (2) | JP2013503853A (en) |
| KR (1) | KR20120046795A (en) |
| CN (1) | CN102497778A (en) |
| AU (1) | AU2010290795B2 (en) |
| CA (1) | CA2772191A1 (en) |
| ES (1) | ES2575218T3 (en) |
| NZ (1) | NZ599082A (en) |
| SG (2) | SG10201405392RA (en) |
| WO (1) | WO2011027363A2 (en) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011027363A2 (en) * | 2009-09-04 | 2011-03-10 | Munisekhar Medasani | Method of treatment of neurodegenerative or neuro-muscular degenerative diseases and therapeutic agent to treat the same |
| KR101423005B1 (en) | 2013-10-17 | 2014-07-28 | 강윤식 | Bowel Cleansing Composition |
| CN103739578B (en) * | 2013-12-20 | 2016-07-13 | 李玉成 | Hydrogen citrate Zine ascorbic acid and its preparation method and application |
| WO2018039526A1 (en) * | 2016-08-25 | 2018-03-01 | Wright State University | Treatment of neurodegenerative disorders and pain |
| CN111511358A (en) * | 2017-12-26 | 2020-08-07 | 花王株式会社 | Agent for improving cognitive function |
| CN113423408A (en) * | 2018-11-14 | 2021-09-21 | (株)纳斯摩仕 | Composition for treating and preventing neurodegenerative diseases comprising aptamer as active ingredient |
| CN109662960A (en) * | 2018-12-14 | 2019-04-23 | 华中科技大学 | Mannitol is preparing application and pharmaceutical composition in the drug for treating Alzheimer disease |
| JP7506903B2 (en) * | 2019-11-01 | 2024-06-27 | 日本メナード化粧品株式会社 | IL-37 production promoter |
| KR102293111B1 (en) * | 2019-11-26 | 2021-08-25 | (주)큐엘바이오 | Composition for improving cognitive function, memory and activity comprising mixture of Schizandra chinensis extract and ascorbic acid as effective component |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8624628D0 (en) * | 1986-10-14 | 1986-11-19 | Scras | Soluble/splitable tablets |
| US4956391A (en) * | 1988-08-17 | 1990-09-11 | Sapse Alfred T | Protected complex of procaine for the treatment of symptoms from narcotics addiction, tinnitus and alzheimer's disease |
| US5696109A (en) * | 1992-12-07 | 1997-12-09 | Eukarion, Inc. | Synthetic catalytic free radical scavengers useful as antioxidants for prevention and therapy of disease |
| US7582786B2 (en) * | 1992-12-07 | 2009-09-01 | Eukarion Inc. | Synthetic catalytic free radical scavengers useful as antioxidants for prevention and therapy of disease |
| US5888534A (en) * | 1995-06-13 | 1999-03-30 | Pentech Pharmaceuticals, Inc. | Controlled release of drugs delivered by sublingual or buccal administration |
| US5738873A (en) * | 1996-09-27 | 1998-04-14 | Herman Bleiweiss | Pharmaceutical formulations and methods for treating patients suffering from diseases that cause muscular hypotonia |
| PT1352654E (en) * | 2000-12-22 | 2006-06-30 | Astellas Pharma Inc | INJECTIONS OF FAMOTIDINA. |
| FR2842422B1 (en) * | 2002-07-16 | 2006-06-30 | Univ Aix Marseille Ii | COMPOSITIONS FOR THE TREATMENT OF PERIPHERAL NEUROPATHIES, PREPARATION AND USES |
| CN1826060B (en) * | 2003-07-21 | 2010-06-09 | 荷兰联合利华有限公司 | Aiding of cognitive function |
| US20060083727A1 (en) * | 2004-07-15 | 2006-04-20 | Nanobac Pharmaceuticals, Inc. | Methods and compositions for the treatment of diseases characterized by calcification and/or plaque formation |
| US7731993B2 (en) * | 2004-11-17 | 2010-06-08 | Lindsey Berkson | Composition for treating a dermal anomaly |
| CA2675745A1 (en) * | 2007-01-18 | 2008-07-24 | Mark A. Pinsky | Materials and methods for delivering antioxidants into the skin |
| KR100815277B1 (en) * | 2007-04-27 | 2008-03-19 | 주식회사 케이티앤지 | Antihyperlipidemia Agent Comprising Red Ginseng Acid Polysaccharide and Lycium Chinense Extract |
| IL188681A0 (en) | 2008-01-09 | 2008-12-29 | Amino Acid Solutions Inc | Pharmaceutical compositions and methods utilizing a d-amino acid |
| US20110158969A1 (en) * | 2008-02-28 | 2011-06-30 | Henry Ford Health System | Compositions and methods for using stromal cells to enhance treatment of central nervous system injuries |
| WO2011027363A2 (en) * | 2009-09-04 | 2011-03-10 | Munisekhar Medasani | Method of treatment of neurodegenerative or neuro-muscular degenerative diseases and therapeutic agent to treat the same |
-
2010
- 2010-09-02 WO PCT/IN2010/000583 patent/WO2011027363A2/en active Application Filing
- 2010-09-02 AU AU2010290795A patent/AU2010290795B2/en not_active Ceased
- 2010-09-02 JP JP2012527449A patent/JP2013503853A/en active Pending
- 2010-09-02 EP EP10813434.7A patent/EP2473037B1/en active Active
- 2010-09-02 NZ NZ599082A patent/NZ599082A/en not_active IP Right Cessation
- 2010-09-02 ES ES10813434.7T patent/ES2575218T3/en active Active
- 2010-09-02 US US13/391,516 patent/US8962039B2/en not_active Expired - Fee Related
- 2010-09-02 CN CN2010800374194A patent/CN102497778A/en active Pending
- 2010-09-02 KR KR1020127008735A patent/KR20120046795A/en not_active Application Discontinuation
- 2010-09-02 SG SG10201405392RA patent/SG10201405392RA/en unknown
- 2010-09-02 SG SG2012014635A patent/SG178942A1/en unknown
- 2010-09-02 CA CA2772191A patent/CA2772191A1/en not_active Abandoned
-
2015
- 2015-11-30 JP JP2015232574A patent/JP6157572B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| JP6157572B2 (en) | 2017-07-05 |
| US20120164245A1 (en) | 2012-06-28 |
| ES2575218T3 (en) | 2016-06-27 |
| WO2011027363A2 (en) | 2011-03-10 |
| US8962039B2 (en) | 2015-02-24 |
| CN102497778A (en) | 2012-06-13 |
| AU2010290795A1 (en) | 2012-04-19 |
| SG178942A1 (en) | 2012-04-27 |
| JP2016074708A (en) | 2016-05-12 |
| NZ599082A (en) | 2014-06-27 |
| AU2010290795B2 (en) | 2015-12-10 |
| CA2772191A1 (en) | 2011-03-10 |
| JP2013503853A (en) | 2013-02-04 |
| EP2473037A2 (en) | 2012-07-11 |
| EP2473037A4 (en) | 2013-05-08 |
| WO2011027363A3 (en) | 2011-06-30 |
| EP2473037B1 (en) | 2016-03-09 |
| KR20120046795A (en) | 2012-05-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG10201405392RA (en) | Method of treatment of neurodegenerative or neuro-muscular degenerative diseases andtherapeutic agent to treat the same | |
| EP2432476A4 (en) | Methods for treating or preventing ophthalmological diseases | |
| PL2512470T3 (en) | Ppar-sparing thiazolidinediones and combinations for the treatment of neurodegenerative diseases | |
| ZA201300831B (en) | Corticosteroids for the treatment of joint pain | |
| EP2440222A4 (en) | Compositions and methods for prevention and treatment of brain diseases and conditions | |
| EP2273882A4 (en) | Bioactive compounds for treatment of cancer and neurodegenerative diseases | |
| HK1169804A1 (en) | Methods for treatment of pain | |
| ZA201106730B (en) | Methods of treatment using combination therapy | |
| EP2515926A4 (en) | Compositions and methods for the treatment of angiogenesis-related eye diseases | |
| HK1176870A1 (en) | Method for treatment of diseases | |
| GB0904427D0 (en) | Treatment of diseases related to hyperactivity of the complement system | |
| IL213703A0 (en) | Compounds and methods for the treatment of pain and other diseases | |
| IL215054A0 (en) | Compositions and methods for prevention and treatment of neurodegenerative diseases | |
| EP2361627A4 (en) | Composition for prevention or treatment of eye diseases | |
| WO2011062762A3 (en) | Angiogenin and variants thereof for treatment of neurodegenerative diseases | |
| EP2244702A4 (en) | Treatment of neural diseases or conditions | |
| GB0804663D0 (en) | Treatment of diseases related to hyperactivity of the complement system | |
| EP2415474A4 (en) | Pharmaceutical composition for treatment or prevention of ophthalmic diseases |